• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Innovation Award
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
  • Members
    • Member Registration
    • Forgot Password

English

ALS Clinical Trials (ALS TDI)

February 27, 2018 by

People like you diagnosed with ALS play the most important role in the discovery and development of effective treatments and cures. Your participation in a clinical trial provides researchers with the data they need to determine whether or not a potential treatment ought to move closer to being available to all those with ALS. The ALS Therapy Development Institute is unbiased in listing clinical trials, providing information on all those enrolling worldwide. We encourage you to browse trials below and to subscribe to the clinical trial mailing list which will email you once a month with an update on changes to trials listed in this database.

ALS TDI Webinars

February 27, 2018 by

Each month, ALS TDI brings together researchers from our lab and others for a conversation about an important topic to patients today. These can be on a specific trial, an emerging technology, or a broad theory gaining notoriety in the effort to combat ALS. These conversations are designed to ask these researchers direct questions and to provide a place where YOU and YOUR family can speak directly to those working on your behalf at ALS TDI and other labs. These webinars are recorded, but we encourage folks to join us live as your questions and interaction with these researchers is incredibly important.

ALS Forum

February 27, 2018 by

Welcome to the ALS Forum. We were started in 2000 by the ALS Therapy Development Foundation (now Institute), which continues to moderate with the help of long-time forum members. The purpose of this forum is to exchange information about ALS, scientific advances in ALS, and treatments for ALS. Forum members include people living with ALS today as well as their care providers, family members, friends, neurologists as well as neurodegenerative disease researchers and pharmaceutical executives. We encourage an open dialogue and the sharing of ideas and opinions. However, bad language, disparaging remarks, personal attacks, marketing, or inappropriate remarks will be removed and may lead to termination of forum privileges. If you have any questions about the use of this forum, or experience difficulties, please email us at info@als.net.

What is ALS?

February 27, 2018 by

Every 90 minutes someone is diagnosed with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder. Each case is different, and the community of people with ALS and the care providers involved with ALS TDI share their experiences to help those newly diagnosed and their families. Advancements in ALS research have provided significant new insights into ALS, how to stratify those diagnosed, and develop effective treatments and cures…

MND Care

February 27, 2018 by

Welcome to MNDcare – the MND Australia evidence based and best practice website for health, disability, aged and community care professionals – getting motor neurone disease care research into practice.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Go to Next Page »

Primary Sidebar

Back to resources

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login